Skip to content

A Study of Respiratory Muscle Strength in Patients With Late-onset Pompe Disease (LOPD)

A Study of Respiratory Muscle Strength, Including Effort-Independent Measures, in Subjects With Late-Onset Pompe Disease

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02191917
Enrollment
8
Registered
2014-07-16
Start date
2014-10-21
Completion date
2016-06-22
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Late-onset Pompe Disease

Brief summary

Study 701-201 is a study in patients with late-onset Pompe disease (LOPD). The study will test respiratory muscle strength initially and again after 24 weeks in subjects treated or not treated with BMN 701 .

Interventions

PROCEDURERespiratory muscle strength measurements by different techniques.

Sponsors

BioMarin Pharmaceutical
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Willing and able to provide written informed consent, after the nature of the study has been explained, and prior to any study-related procedures * Documented diagnosis with late-onset Pompe disease - At least 18 years of age at study entry * Willing and able to comply with all study procedures

Exclusion criteria

* Requires ventilatory support while awake and in the upright position * Concurrent disease, medical condition, or extenuating circumstance that, in the opinion of the investigator, might compromise patient well-being, study completion, or data collection * Allergy to tools or procedures used for respiratory muscle testing

Design outcomes

Primary

MeasureTime frameDescription
Maximal Inspiratory Pressure (MIP)Baseline, Week 28Pulmonary measure of change in maximal inspiratory pressure (MIP)

Secondary

MeasureTime frameDescription
Maximal Expiratory Pressure (MEP)Baseline, Week 28Pulmonary measure of change in maximal expiratory pressure (MEP)

Countries

United Kingdom, United States

Participant flow

Participants by arm

ArmCount
Overall
All subjects
8
Total8

Baseline characteristics

CharacteristicOverall
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
8 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
8 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race/Ethnicity, Customized
American Indian or Alaska Native
0 Participants
Race/Ethnicity, Customized
Asian
0 Participants
Race/Ethnicity, Customized
Black or African American
0 Participants
Race/Ethnicity, Customized
Native Hawaiian or Other Pacific Islander
0 Participants
Race/Ethnicity, Customized
Other
0 Participants
Race/Ethnicity, Customized
White
8 Participants
Region of Enrollment
United Kingdom
7 Participants
Region of Enrollment
United States
1 Participants
Sex: Female, Male
Female
2 Participants
Sex: Female, Male
Male
6 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 8
other
Total, other adverse events
1 / 8
serious
Total, serious adverse events
0 / 8

Outcome results

Primary

Maximal Inspiratory Pressure (MIP)

Pulmonary measure of change in maximal inspiratory pressure (MIP)

Time frame: Baseline, Week 28

Population: Full Analysis Set (FAS) population includes all enrolled subjects who have at least one study assessment.

ArmMeasureGroupValue (MEAN)Dispersion
OverallMaximal Inspiratory Pressure (MIP)Baseline49.2 cm H2OStandard Deviation 21.7
OverallMaximal Inspiratory Pressure (MIP)Last Visit46.0 cm H2OStandard Deviation 20.93
OverallMaximal Inspiratory Pressure (MIP)Change from Baseline-5.5 cm H2OStandard Deviation 8.38
Secondary

Maximal Expiratory Pressure (MEP)

Pulmonary measure of change in maximal expiratory pressure (MEP)

Time frame: Baseline, Week 28

Population: Full Analysis Set (FAS) population includes all enrolled subjects who have at least one study assessment.

ArmMeasureGroupValue (MEAN)Dispersion
OverallMaximal Expiratory Pressure (MEP)Baseline77.1 cm H2OStandard Deviation 32.39
OverallMaximal Expiratory Pressure (MEP)Last Visit69.0 cm H2OStandard Deviation 24.18
OverallMaximal Expiratory Pressure (MEP)Change from Baseline-11.6 cm H2OStandard Deviation 11.35

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026